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Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder which presents 
with isolated thrombocytopenia and risk of hemorrhage. While most children with ITP promptly 
recover with or without drug therapy, ITP is persistent or chronic in others. When needed, how to 
select second-line therapies is not clear. ICON1, conducted within the Pediatric ITP Consortium of 
North America (ICON), is a prospective, observational, longitudinal cohort study of 120 children 
from 21 centers starting second-line treatments for ITP which examined treatment decisions. 
Treating physicians reported reasons for selecting therapies, ranking the top three. In a propensity 
weighted model, the most important factors were patient/parental preference (53%) and treatment-
related factors: side effect profile (58%), long-term toxicity (54%), ease of administration (46%). 
possibility of remission (45%), and perceived efficacy (30%). Physician, health system, and 
clinical factors rarely influenced decision-making. Patient/parent preferences were selected as 
reasons more often in chronic ITP (85.7%) than in newly diagnosed (0%) or persistent ITP 
(14.3%, p=0.003). Splenectomy and rituximab were chosen for the possibility of inducing long-
term remission (p<0.001). Oral agents, such as eltrombopag and immunosuppressants, were 
chosen for ease of administration and expected adherence (p<0.001). Physicians chose rituximab 
in patients with lower expected adherence (p=0.017). Treatment choice showed some physician 
and treatment center bias. This study illustrates the complexity and many factors involved in 
decision-making in selecting second-line ITP treatments, given the absence of comparative trials. 
It highlights shared decision-making and the need for well-conducted, comparative effectiveness 
studies to allow for informed discussion between patients and clinicians.
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Introduction
Immune thrombocytopenia (ITP) is an uncommon hematologic condition during childhood. 
Despite presenting with severe thrombocytopenia, only 0.4–0.6% of affected children will 
have intracranial hemorrhage (ICH) and <3% will have other severe (non-ICH) bleeding at 
diagnosis.[1, 2] The majority (70–80%) will experience complete resolution of their disorder 
within 12 months from diagnosis [3, 4]. Many such children can be safely managed initially 
with close observation, with the decision to initiate front-line therapy with corticosteroids, 
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anti-D immunoglobulin, or intravenous immunoglobulin (IVIG) based on signs or symptoms 
of mucocutaneous bleeding or bleeding risk [5, 6].
There has been extensive controversy regarding how to manage newly diagnosed children 
with ITP. The indications, timing, and choice of second-line treatment in children with ITP, 
when needed, are more complex and highly variable among treating physicians [7]. Among 
many options are splenectomy, rituximab, oral immunosuppressive agents, thrombopoietin 
receptor agonists (TPO-RA), and intermittent first-line treatments (e.g., IVIG or 
corticosteroids). Each differs in potential short and long-term efficacy and side effect 
profiles. Additional considerations include patient age, different routes of administration, 
dietary considerations, monitoring, and costs, which in turn influence patient, family, and 
physician preference. Therefore, selection of a specific second-line treatment for a child with 
ITP is complex and ideally would be individualized.
In shared decision-making, health care decisions are made together by the patient and/or 
caregiver along with the medical provider. The goal is to fully engage in an informed 
consent model of care by improving communication between providers and their patients or 
caregivers. One recent study suggested a lack of shared decision-making in the care of 
children with ITP [8]. Focus groups have revealed that parents of children with ITP 
commonly have feelings of anxiety and confusion and feel they had little choice in the 
decision for treatment. Physicians also have their own biases, which influence their decision-
making [8–10]. A few studies have attempted to address the importance of decision 
modeling and shared decision-making for first-line ITP therapy [7], but factors involved in 
decision-making around second-line therapies for children with ITP have not been studied.
ICON1 was subsequently designed as a prospective, observational, longitudinal cohort study 
of children starting second-line treatments for ITP to be conducted by the Pediatric ITP 
Consortium of North America (ICON) [11]. In this report, the factors physicians prioritize 
when selecting second-line treatments for individual patients were explored.
Methods
ICON1 Study Design
Prior to study initiation, a focus group was convened to determine which factors would be 
ascertained in assessment of physician decision-making. This focus group, consisting of 13 
investigators with expertise in ITP, designed a conceptual model (Supplemental Figure 1), 
which was then used in ICON1. The process by which the conceptual model was derived is 
described in the Supplemental materials.
ICON1 is a longitudinal observational cohort of 120 children with ITP requiring second-line 
treatments. Participants were enrolled from 2013–2015 at 21 centers following local IRB 
approval. All participants had their caregivers provide consent for participation in the study. 
Enrollment requirements included: age 1–17 years and starting a second-line treatment (i.e., 
all treatments except observation, IVIG, corticosteroids or anti-D immunoglobulin). Patients 
with secondary ITP were included except for Evans syndrome with prior or ongoing 
autoimmune hemolytic anemia. Baseline and follow-up demographic and clinical 
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characteristics were recorded, including disease duration, response to prior treatments, and 
platelet counts.
Hematologists at each ICON site were invited by site investigators to participate in the study. 
By submitting completed patient forms, physicians thus provided their own consent for 
information in the forms to be used to understand physician choice. The physician primarily 
involved in the treatment decision completed the questionnaire after the visit in which the 
treatment decision was made. The questionnaire listed all the factors outlined by the focus 
group, and physicians selected all relevant factors and ranked their top 3 factors. Physicians 
recorded the impact of ITP on the patient’s HRQoL using a 5 point scale.
Statistical Methods
Data were entered into a REDCap database, which was exported to SAS for analysis [12]. 
Frequencies and means were computed for descriptive purposes. Fisher’s exact test was used 
to compare treatment choice on categorical variables. Patient age was compared between 
treatment choices using the Kruskal-Wallis test. Treatments were selected for comparison if 
they were used in at least 15 evaluable patients in the study cohort. Oral immunosuppressant 
agents (n=19) were grouped for comparison and included 6-mercaptopurine (n=13), 
azathioprine (n=1), mycophenolate (n=3), and sirolimus (n=2). To better understand reasons 
for treatment choice, physicians were asked to select and rank the top three reasons for their 
treatment choice. A weighted summary of reasons for treatment choice was created by 
giving the top reason a weight of three, the second reason a weight of two, and the third 
reason a weight of one. These weights were used to determine the most important reasons 
for treatment choice. Distribution of treatment choice between centers was restricted to five 
centers with adequately large sample sizes (n ≥ 8 patients) and was compared using Fisher’s 
exact test.
Results
ICON1 Demographics
One hundred twenty patients were enrolled in the study (Table 1); the majority (85%, 
n=102) had primary ITP [13]. The types of secondary ITP included: Evans syndrome (n=9), 
underlying immunodeficiencies (n=5), rheumatologic conditions (n=3), and inflammatory 
bowel disease (n=1). The median age was 11.7 years (range 1.2–17.8 years). The majority of 
children had chronic ITP (n=64, 53%) but a significant proportion were newly diagnosed 
(n=19, 16%). Children had received a median of 3 prior treatments (range 0–8) with 47 
(39%) patients having received at least one prior second-line treatment, including rituximab 
(n=12, 10%), romiplostim (n=11, 9%), eltrombopag (n=10, 8%), 6-mercaptopurine/
azathioprine (n=6, 5%), and/or splenectomy (n=3, 3%). Two patients had no prior treatments 
and were monitored with observation only.
Patients were treated by physicians who were a median of 8 years (range 1–44 years) from 
completion of fellowship. The majority of treating physicians were seeing >20 patients per 
year with ITP.
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At enrollment, patients were started on the following second-line treatments: rituximab 
(43/120, 36%), romiplostim (31/120, 26%), eltrombopag (20/120, 17%), oral 
immunosuppressant agents (19/120, 16%), splenectomy (4/120, 3%), and dapsone (3/120, 
3%). Treatment groups were not different with regard to the number of patients with chronic 
ITP (p=0.97) or by those who had been treated previously with second-line treatments 
compared with those who had never received a second-line treatment (p=0.10).
Overall Reasons for Selecting Treatments
In the non-weighted analysis, the most important factors guiding treatment decisions were 
patient and parental preference (53%) and treatment-related factors, including the side effect 
profile (58%), long-term toxicity (54%), ease of administration (46%), possibility of 
remission (45%), and efficacy (30%). Physician factors, such as experience and citing 
published guidelines, rarely influenced decision-making with only 9% of physicians giving 
published guidelines as a reason for choice of therapy. Additionally, 38% of physicians did 
not endorse any patient clinical factors (i.e., frequency of bleeding, expected compliance, 
response to other therapies, age, comorbidities) as key in their decision-making. Health 
system factors, such as insurance approval or distance from the closest medical center, rarely 
were chosen as having an impact on treatment choice.
In the propensity weighted analysis, the most commonly selected factors included possibility 
of long-term remission, parental and patient preference, side effect profile, and ease of 
administration (Figure 1).
Patient and parent preferences were reasons for choosing a treatment more often in patients 
with chronic ITP (85.7%) than in those with newly diagnosed (0%) or persistent (14.3%, 
p=0.003). The potential for long-term remission as a reason for selecting a treatment tended 
to be lower in newly diagnosed patients (16.7%) but was not significantly different than 
patients with persistent (45.8%) or chronic ITP (37.5%, p=0.16). Long-term remission was 
not selected more often in patients with primary versus secondary ITP (44% vs. 50%, 
p=0.80).
Reasons for Selecting Specific Treatments
Certain treatments tended to be favored for specific reasons (Figure 2). A significant 
determinant of choosing splenectomy or rituximab (p<0.001) was the possibility of long-
term remission. This reason was endorsed in 100% and 91% of cases respectively when 
splenectomy or rituximab was chosen. Oral agents, such as eltrombopag and 
immunosuppressant agents, were significantly more likely to be chosen due to ease of 
administration and expected adherence (p<0.001); this reason was endorsed in 95% of those 
starting eltrombopag and 84% of those starting oral immunosuppressants. Physicians 
indicated expected efficacy as a reason more frequently for romiplostim (61%) as compared 
to eltrombopag (30%; p<0.001) and were more likely to choose rituximab in patients in 
whom there was lower anticipated adherence (p=0.017).
Among the most frequent reasons for favoring an individual treatment, the specific treatment 
related factors were major determinants (Table 2). For rituximab, 93% of physicians 
endorsed at least one treatment factor; for oral immunosuppressants, romiplostim, and 
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eltrombopag, 100% of physicians endorsed at least one treatment factor. Although treatment 
related factors were the major determinants, the specifics of the factors differed among them. 
For romiplostim, the side effect profile (68%) was the most important treatment factor. For 
rituximab, the possibility of cure was a major treatment factor (91%), whereas for oral 
immunosuppressant agents and eltrombopag, ease of administration (84% and 95%, 
respectively) was most important. The oral treatments, eltrombopag and oral 
immunosuppressants, were also selected for similar patient-centered reasons, including 
patient adherence and preference.
In all patients undergoing splenectomy (n=4), this option was selected both due to the 
possibility of long-term remission and patient or provider preference. Those patients who 
underwent splenectomy had a median age of 16.2 years (range 15–17 years) and 75% had 
chronic ITP. These patients had received a median of 1 prior second-line treatments (range 
1–2), which included rituximab (n=3) and eltrombopag (n=1). One splenectomized patient 
had no prior second-line treatments.
Physician/Patient Factors and Treatment Choice
There was no relationship between the age of the patient and the treatment selected 
(p=0.20). The experience of the physician, in terms of the number of years in practice, also 
did not correlate with the second-line treatment chosen (p=0.25).
There was a tendency for individual physicians to select certain treatments. When restricting 
the analysis to the five highest enrolling centers (n=61; range 8–17 patients per center), there 
was an association between treatment choice and treatment center (p=.008). In particular, 
rituximab was selected for at least half the patients at two centers, while romiplostim was 
selected for more than half of the patients at two other centers.
While low patient HRQoL may have been a reason second-line treatment was initiated, the 
physician report of the impact of ITP on patient HRQoL did not differ by treatment at the 
time of treatment selection (p=0.169). Although when asked to supply reasons for selecting 
particular therapies, physicians ranked patient adherence as an important reason, physician 
report of patient adherence did not actually correlate with any particular second-line 
treatment choice (p=0.29). In addition, the worst non-skin bleeding in the previous week did 
not correlate with the choice of treatment (p=0.73).
Discussion
Management of childhood ITP, particularly when persistent or chronic, can be challenging. 
The process of selecting a second-line treatment is complex with many issues affecting the 
hematologist’s choice of therapy for a given patient. ITP decisions may readily change in the 
course of treatment and are influenced by a variety of factors. The study described here is 
the first to assess physician treatment decisions in second-line therapy for pediatric ITP. The 
result was that patient preference and physician perception of treatment characteristics are 
the primary drivers of treatment choice.
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Individual treatments were most often chosen for similar reasons. For example, clinicians 
chose splenectomy and rituximab because of the possibility of long-term remission desired 
by the patient and family. The most robust data regarding long term remission is available 
for splenectomy, a longstanding historical treatment for ITP, for which there is some 
confidence in its efficacy and long-term remission rates [14–17]. Nevertheless, only 6 of the 
120 patients in this study had already undergone splenectomy at the time of enrollment and 
just 4 additional patients underwent the procedure during the study. This presumably 
represents the trend in both children and adults to defer or avoid splenectomy in favor of 
medical therapies, given the concerns about long-term sequelae of splenectomy [18, 19]. 
Rituximab, on the other hand, is a relatively newer treatment for ITP, and the long-term 
remission data are not as robust [20]. While initial response rates were encouraging with 
rituximab, long-term remission at 5 years now appears to be much lower (20–30%) and 
consistent with expected spontaneous remission rates [20]. Based on the ICON1 data, the 
perceived long term efficacy of rituximab among pediatric hematologists and patients may 
be higher than that demonstrated in clinical trials.
Eltrombopag was approved for children ≥1 year of age in 2015, and romiplostim, although 
used off-label, is not yet approved for use in pediatric ITP. Most patients in this study were 
enrolled during 2013 to 2015 before eltrombopag was FDA approved for children. As 
expected, long-term remission was not prioritized with regard to selecting TPO-RA therapy. 
Data about potential efficacy and side effects with these agents is evolving [21–24]. 
However, the TPO-RAs were also selected for a perceived reduction of toxicity, presumably 
because they avoid immunosuppression. While there has been some evolution of data over 
the course of this study, in general, physician practice did not change and prescribing 
patterns were similar over time.
Practice varied by center, which may reflect the practice of single physicians at these 
centers, physicians’ perception of efficacy and potential side effects of individual treatments, 
or dissemination of novel information about current treatments for ITP. Although physicians 
reported that they did not select treatments based on their own comfort level, these center 
specific practices suggest that physician factors and institutional biases do influence 
treatment selection. While parent and patient preference is a primary reason for selecting a 
treatment, this is often strongly influenced by the treating physician’s experience and the 
manner in which information is presented to families [25, 26]. The lack of comparative 
effectiveness studies for evidence-based decision-making increases the potential for 
physician and center-specific biases.
Study data suggest that the selection of individual treatments did not correlate with the 
physician’s perception of the effect of ITP on patient HRQoL. In most patients starting a 
second-line treatment, ITP has a significant negative effect on HRQoL. However, given the 
lack of data about differences among treatments in improving patient HRQoL, it would have 
been surprising if the physician’s assessment of the patient’s baseline HRQoL did correlate 
with treatment selection. As HRQoL and fatigue measures are integrated into trials and more 
is learned about the impact of treatment on HRQoL, patient baseline HQoL may factor into 
decision making in selecting specific treatments. Age, a factor that may play an important 
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role in determining whether or not to initiate treatment to raise the platelet count, did not 
influence the type of therapy selected.
This study highlights several important points regarding second-line agent use. First, many 
patients will receive second-line therapy prior to being diagnosed with chronic ITP. 
However, a number of treatments have only been studied in children with chronic ITP, and 
their efficacy and benefits earlier in the disease are less understood. Second, guidelines with 
low-grade recommendations resulting from a lack of randomized trials have resulted in 
physicians relying more on personal preferences and individual therapy characteristics. This 
emphasizes the need for clinical trials to define patient characteristics carefully and to 
collect data on patient-related endpoints similarly to allow for comparison of endpoints even 
if a given study is not conducted in a randomized fashion. The physicians who participated 
in this study also have a specific interest in ITP which may have influenced their reliance on 
guidelines compared with other practitioners. Furthermore, guidelines should be routinely 
updated to reflect emerging evidence. Lastly, health-system factors in this study did not 
seem to impact decision-making; however, this may not be the case in many countries where 
access to certain treatments is more limited.
This study has several limitations. Some physician’s decisions were represented multiple 
times at certain centers. Since we did not capture data to discern between participating 
physicians, we cannot be certain whether patients from a site are managed by the same 
physician. Second, physicians ranked the top three factors in selecting an individual 
treatment. These factors are likely not independent and accounting for the interaction 
between factors is difficult to model. Therefore, treatment decision making may be much 
more complex than our model, and the model used may not adequately reflect the influence 
of all the factors that helped to guide the decision. In particular, certain factors may be taken 
for granted, consciously or unconsciously, from previous experience with the patient, 
disease, or treatment. Additionally, physicians are influenced by the expected results of 
treatment, both efficacy and toxicity, and these may change over time as new information 
and treatments become available. Nevertheless, although center-specific preferences were 
clear, the centers with >15 enrolled participants had variability in the treatment selected.
This study illustrates the complexity of decision making in the absence of comparative trials. 
Perhaps even more importantly, it also emphasizes the need for ongoing clinical research to 
better define populations of ITP patients most likely to benefit from specific interventions 
and to compare treatments in these populations. This study also underscores the need for a 
shared decision-making model to ensure a comprehensive consideration of all factors 
important to both physicians and their patients and families. Fully incorporating and 
individually prioritizing the key factors for a given patient requires extensive discussion to 
fully inform and engage the patient in the treatment decision. Finally, by describing our 
collective experience, the authors anticipate that this study may serve as a basis for the 
design of clinical trials which will adequately address knowledge gaps and inform patient 
and clinician decision-making.
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Figure 1. 
Overall highest ranked reasons for treatment choice. The top 3 reasons are highlighted in 
black and are all related to either medication characteristics or family preferences.
The most common other reasons (indicated with hash marks) included: relevant other 
medical problems (n=6), fatigue (n=5), menstrual bleeding (n=2), surgical procedure (n=2).
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Figure 2. 
Ranked reasons for physician choice by second-line therapy. Individual therapies were 
examined and weighted scores were assigned to reasons for physician choice.
Scores in this figure are re-scaled so that equally long bars indicate that the reason was 
equally ranked for each treatment. Reasons that were less important are excluded from the 
figure.
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Table 1
Demographic Features of ICON1 participants
n=120
Age at Enrollment (y); Median (range) 11.7 (1.2–17.8)
Primary ITP N (%) 102 (85%)
Secondary ITP 18 (15%)
Platelet Count in Prior Month (%, total)
<10×109/L 62 (52%)
10–19×109/L 26 (22%)
20–29×109/L 13 (11%)
≥30×109/L 14 (12%)
Unknown 5 (4%)
Phase of ITP Newly Diagnosed 19 (16%)
Persistent 37 (31%)
Chronic 64 (53%)
Number of Prior Treatments* Median (range) 3 (0–8)
Number of Prior First Line Treatments 2 (0–5)
Number of Prior Second Line Treatments 0 (0–5)
Number with no Prior First-Line Treatments 2 (1.6%)
Number with no Prior Second-Line Treatments 73 (61%)
Prior Treatments (%, total)
IVIG 115 (96%)
Prednisone 94 (78%)
Anti-D globulin 27 (23%)
Rituximab 17 (14%)
Romiplostim 12 (10%)
6-Mercaptopurine/Azathioprine 9 (8%)
Eltrombopag 8 (7%)
Splenectomy 6 (5%)
Dapsone 5 (4%)
Mycophenolate 3 (3%)
*Number reflects absolute number of different treatments and does not account for repeated courses of treatments.
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Table 2
Most Frequent Determinants of Treatment Choice in Selecting Second-line ITP Therapies
Treatment Reasons for Selecting a Specific Treatment Number of
Times
cited (%)
Top
ranked
reasons
Rituximab n=43 Possibility of long-term remission 39(91%) 1
Parental or Patient preference 23(53%) 2
Physician Comfort / Experience with the treatment 22(51%) 5*
Minimal long-term toxicity 20(47%) 4
Side effect profile 17(40%) 5*
Response to Prior Treatments 14(33%) 3
Oral Immunosuppressants n=19 Ease of administration 16(84%) 1
Minimal long-term toxicity 14(74%) 2
Physician Comfort / Experience with the treatment 12(63%) 5
Side effect profile 11(58%) 3
Expected Compliance 11(58%)
Parental or Patient preference 8 (42%)
Possibility of long-term remission 7(37%) 4
Romiplostim n=31 Side effect profile 21(68%) 2*
Perceived Efficacy 19(61%) 1
Parental or Patient preference 18(58%) 2*
Physician Comfort / Experience with the treatment 17(55%) 3
Minimal long-term toxicity 14(45%)
Expected Compliance 13(42%)
Ease of administration 11(35%) 5
Response to Prior Treatments 10(32%) 4
Eltrombopag n=20 Ease of administration 19(95%) 1
Side effect profile 14(70%) 2
Minimal long-term toxicity 11(55%) 4
Parental or Patient preference) 11(55%) 3
Expected Compliance 10(50%)
Level of activity 7(35%)
Response to Prior Treatments) 7(35%)
Physician Comfort / Experience with the treatment 7(35%)
Perceived Efficacy 6(30%) 5
*
tied ranking
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